Should high-dose N-acetylcysteine be given in cases of massive paracetamol overdoses: A narrative review

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Philip Ahle Erichsen, Kim Dalhoff, Michael Asger Andersen
{"title":"Should high-dose N-acetylcysteine be given in cases of massive paracetamol overdoses: A narrative review","authors":"Philip Ahle Erichsen,&nbsp;Kim Dalhoff,&nbsp;Michael Asger Andersen","doi":"10.1111/bcpt.14051","DOIUrl":null,"url":null,"abstract":"<p>N-acetylcysteine (NAC) is regarded as an effective treatment of paracetamol overdoses. However, in cases of “massive” paracetamol overdoses, recent studies indicate that patients may not be sufficiently treated with the standard dose of NAC (300 mg/kg over 20–21 h). The subject is further complicated because “massive overdoses” and “high-risk” are defined differently; some studies use the ingested amount (e.g., &gt;40 g), and some studies use blood concentrations of paracetamol and transaminases. This narrative review investigates whether high-dose NAC significantly decreases the risk of hepatotoxicity in patients with massive paracetamol overdoses. Three observational studies were analysed; one study with 373 patients found no significant difference (odds ratio [OR]: 1.27, 95% confidence interval [CI]: 0.49–3.29). One study with 79 patients found a significant difference (OR: 0.27, 95% CI: 0.08–0.94). The third study with 89 patients found a significant difference in hepatoxicity between the groups (<i>p</i> = 0.043). There are no solid evidence to support that treatment with high-dose NAC significantly reduces the rate of hepatotoxicity in patients presenting with massive paracetamol overdoses. Differences in inclusion criteria in the included studies make the studies incomparable. This paper shows that standardized inclusion is needed to determine whether a high-dose NAC regimen should be included in clinical practice.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 3","pages":"285-294"},"PeriodicalIF":2.7000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14051","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.14051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

N-acetylcysteine (NAC) is regarded as an effective treatment of paracetamol overdoses. However, in cases of “massive” paracetamol overdoses, recent studies indicate that patients may not be sufficiently treated with the standard dose of NAC (300 mg/kg over 20–21 h). The subject is further complicated because “massive overdoses” and “high-risk” are defined differently; some studies use the ingested amount (e.g., >40 g), and some studies use blood concentrations of paracetamol and transaminases. This narrative review investigates whether high-dose NAC significantly decreases the risk of hepatotoxicity in patients with massive paracetamol overdoses. Three observational studies were analysed; one study with 373 patients found no significant difference (odds ratio [OR]: 1.27, 95% confidence interval [CI]: 0.49–3.29). One study with 79 patients found a significant difference (OR: 0.27, 95% CI: 0.08–0.94). The third study with 89 patients found a significant difference in hepatoxicity between the groups (p = 0.043). There are no solid evidence to support that treatment with high-dose NAC significantly reduces the rate of hepatotoxicity in patients presenting with massive paracetamol overdoses. Differences in inclusion criteria in the included studies make the studies incomparable. This paper shows that standardized inclusion is needed to determine whether a high-dose NAC regimen should be included in clinical practice.

Abstract Image

大量扑热息痛过量时是否应给予大剂量 N-乙酰半胱氨酸?叙述性综述。
N-乙酰半胱氨酸(NAC)被认为是治疗扑热息痛过量的有效药物。然而,最近的研究表明,在对乙酰氨基酚 "大量 "过量的情况下,使用标准剂量的 NAC(300 毫克/千克,20-21 小时)可能无法充分治疗患者。由于 "大量过量 "和 "高风险 "的定义不同,因此这一问题变得更加复杂;有些研究使用摄入量(如大于 40 克),有些研究使用扑热息痛和转氨酶的血液浓度。本叙述性综述探讨了大剂量 NAC 是否能显著降低大量扑热息痛过量患者的肝毒性风险。对三项观察性研究进行了分析;其中一项包含 373 名患者的研究发现,两者之间没有明显差异(几率比 [OR]:1.27,95% 置信区间 [CI]:0.49-3.29)。一项有 79 名患者参与的研究发现差异显著(OR:0.27,95% 置信区间[CI]:0.08-0.94)。第三项针对 89 名患者的研究发现,两组患者的肝毒性存在显著差异(P = 0.043)。没有确凿证据证明大剂量 NAC 治疗可显著降低大量扑热息痛过量患者的肝毒性发生率。所纳入研究的纳入标准存在差异,导致这些研究无法进行比较。本文表明,要确定是否应在临床实践中采用大剂量 NAC 方案,需要标准化的纳入标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
6.50%
发文量
126
审稿时长
1 months
期刊介绍: Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信